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Summary Screen-detected breast cancers are smaller than those detected in symptomatic populations and, for
any given size, they are associated with fewer lymph node metastases. The management ofaxillary lymph nodes
in patients with screen-detected breast cancer remains controversial. We have previously reported that
prevalence (initial screen)-detected cancers are associated with nodal metastases in 17.4% of cases overall.
Cancers < 10 mm, of any grade, are associated with metastases in only 5% of cases, and grade I cancers
<30 mm are not associated with metastases. This led to our recommendation that axillary surgery is
unnecessary for these groups of women. The present study compared the nodal status of cancers detected at the
prevalence and first incidence (second) screens in order to determine whether our recommendation is
appropriate for cancers detected at the first incidence screen. Overall, 30.1% of cancers detected in the first
incidence screen presented axillary nodal metastases. At all size ranges, cancers detected at the first incidence
screen were associated with significantly more lymph node metastases than prevalence-detected cancers. In
particular, cancers A 10 mm were associated with metastases in 14.3% of cases. With the possible exception of
grade I cancers, we believe that surgical staging of the axilla is essential for cancers detected at the first
incidence screen, irrespective of size.
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Breast screening aims to reduce mortality by early detection
and treatment of breast cancer. For this to be achieved,
screen-detected cancers should have a better prognosis than
those presenting symptomatically. Screen-detected breast
cancers are smaller than those detected in a non-screened
population with more favourable histological grade and type
(Crisp et al., 1993; Tabar et al., 1992). For any given size,
screen-detected cancers are associated with fewer lymph node
metastases than those detected in non-screened populations
(Anderson et al., 1991). However, the Edinburgh Breast
Screening Trial reported that these tumour variables differ
between cancers detected at the prevalence (initial screen) and
incidence (second or subsequent) screening rounds (Anderson
et al., 1986, 1991). Although patient numbers in this study
were relatively small, lymph node positivity was found to be
24.5% in the prevalence screen (PS) and 31.3% for incidence
screen (IS)-detected cancers.
The optimum surgical management of axillary lymph
nodes in women with symptomatic or screen-detected breast
cancer remains highly controversial. Some authors recom-
mend axillary staging in all patients with operable invasive
breast cancer to gain maximum prognostic information and
to allow selection of patients for systemic adjuvant therapy
(Fentiman, 1991). However, if we could identify those
patients with breast cancer at low risk of nodal involve-
ment, the number of patients needing axillary dissection
would be reduced, resulting in a subsequent decrease in
patient morbidity, operating time and cost. Several authors
have suggested that axillary dissection can be abandoned for
small (< 1 cm) symptomatic cancers, in view of the low rates
of lymph node involvement. Instead patients could be
selected for adjuvant therapy on the basis of primary
tumour characteristics alone, with axillary dissection adding
little if anything to the decision-making process (Silverstein et
al., 1994; Chada et al., 1994; Cady, 1994).
More recently, the low incidence of nodal metastases in
prevalence screen-detected cancers has led to claims that
axillary surgery is unnecessary for at least some of these
patients. We have previously recommended that women with
prevalence screen-detected breast cancer <1 cm diameter of
any grade, or those with grade I tumours <3 cm diameter,
can be spared axillary surgery because of an acceptably low
risk of nodal metastases (Walls et al., 1993). The frequency of
nodal involvement and, therefore, the indications for axillary
surgery for cancers detected at the first incidence screen (FIS)
are unknown.
The aim of this study was to compare the lymph node
status of cancers detected at the PS and FIS, to determine
whether our recommendations for axillary surgery remain
appropriate for small and well-differentiated cancers detected
at the FIS.
Patients and methods
Women aged between 50 and 64 years who presented for
screening mammography to the Greater Manchester Breast
Screening Unit were included in the study. Women over 64
years and those self-referring to the unit were excluded.
Cancer size, grade and lymph node status were compared
between the first 293 women with invasive cancer detected at
the PS up to February 1993 and the first 103 women with
invasive cancer detected at the FIS up to July 1994. All
patients with FIS-detected cancers had been reported to have
normal mammograms 3 years earlier. Patients with interval
cancers were not included in the study.
The percentage of palpable and impalpable cancers was
similar in the two screens: 57% and 43% respectively.
Patients with palpable invasive breast cancer underwent
wide local excision or mastectomy after preoperative
diagnosis by fine-needle aspiration cytology or core-cut
biopsy whenever possible. Impalpable lesions were excised
using localisation techniques. During the early period of this
study, stereotactic fine-needle aspiration cytology was in its
infancy in our unit, and the majority of patients with
impalpable cancer had preoperative cytology that was
inadequate for diagnosis.
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Our policy is to perform a level III axillary dissection
either during the primary procedure, if a preoperative
diagnosis is available, or as a subsequent procedure if the
diagnosis is obtained by a localisation procedure.
Cancer grade was determined by the modified Bloom and
Richardson grading system (Elston, 1987). Invasive ductal
carcinomas of no special type (NST) were graded I, II or III.
Lobular carcinomas were graded II, and other tumours of
special type (ST), e.g. mucoid, tubular and cribriform, were
graded I. Cancer size was measured histologically. The total
number of axillary lymph nodes removed and the number of
involved nodes were recorded in each case.
Statistical significance was assessed by chi-squared test,
with analysis of variance.
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Results
Invasive cancer histology and grade
Histological cancer type did not differ significantly between
the two screens. Distribution of cancer grade was similar
between the two screens. Cancers were graded I, II and III in
32.4%, 55.2% and 12.4% of PS-detected cancers, compared
with 29.1%, 53.4% and 17.5% of FIS-detected cancers
respectively.
Invasive cancer size
Invasive cancers were divided into four histological size
categories (Figure 1) A significantly higher proportion o0
cancers < 10 mm was detected in the FIS: 42/103 (40.8%) v6
81/293 (27.6%) in the PS (X2=6.14, P<0.02).
Lymph node status
Of the PS-detected cancers 273/293 (93.2%) underwen
axillary dissection, compared with 80/103 (77.7%) of FIS
detected cancers. As a proportion of the total invasive group
and not just those that underwent axillary dissection, lympl
node positivity increased from 51/293 (17.4%) in the PS tc
31/103 (30.1%) in the FIS (X2=7.48, P<0.01). Of thos
undergoing axillary surgery, the frequency of node metastasi
increased from 51/273 (18.6%) in the PS to 31/80 (38.7%) ir
the FIS (X2= 13.93, P.0.001). No grade I cancers <3 cn
were associated with lymph nodes metastases in either screen
The mean number of nodes cleared from patients witi
nodal involvement was 16.2 in the PS and 14.7 in the FIS
with the mean number of positive nodes being 4.6 and 5.)
respectively. Nine out of 31 (29%) patients in the FIS hac
four or more involved lymph nodes, compared with 13 out o
51 (25.5%) in the PS.
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Figure 1 The distribution of cancer size in the prevalence (OI)
and first incidence (O) screens. The total number of cases in each
group is indicated.
PS n=51 4(5%)
FIS n= 31 6 (14.3%)
11(10%)
7 (23%)
19 (33%)
12 (57%)
17 (45%)
6 (60%)
Figure 2 The relationship between cancer size and lymph node
status for prevalence ([I)- and first incidence (E)-detected
cancers. The total number of cases and percentage in each
group are indicated.
Table I Relationship between cancer size, grade
status for FIS-detected cancers
s
e
If
Is
and lymph node
Size GradeI GradeII GradeIII Node positive
.lomm 17 18 7 6/42 (14.3%)
11 -19mm 10 15 5 7/30 (23.3%)
20-29mm 2 14 5 12/21 (57%)
>30mm 1 8 1 6/10 (60%)
Node positive 0/30 24/55 7/18 31/103
(0%) (43.6%) (38.9%) (30.1%)
At all size ranges, cancers detected in the FIS were
h associated with a higher incidence of nodal metastases
(X2=7.1, P<0.01, Figure 2). In particular, cancers
e <10 mm were associated with nodal metastases in 4/81
is (5%) of PS-detected cases compared with 6/42 (14.3%) of
. FIS-detected cases. The relationship between size, grade and
. lymph node status for FIS-detected cancers is shown in Table
l. I. Corresponding results for PS-detected cancers have been
h reported previously (Walls et al., 1993).
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The United Kingdom breast screening guidelines target the
detection of small breast cancers, but for screening to succeed
and reduce the mortality from breast cancer lesions must be
detected before the development of nodal metastases (Crisp et
al., 1993). Breast screening theory supposes that prevalence
screens are biased towards the detection of slow-growing, less
aggressive cancers, whereas incidence screens detect smaller,
faster growing and biologically more aggressive lesions,
because of the phenomenon of length time bias (Cole, 1980).
Our results are compatible with breast screening theory.
In the two screening rounds, invasive cancers of similar
histological type and almost identical grade were detected. A
greater proportion of cancers detected in the FIS were
< 10 mm in size, but despite this overall lymph node
positivity was significantly higher in the FIS.
Axillary lymph nodes are the main site of regional
metastases from breast cancer. Lymph node status is
recognised to be the most useful marker of distant metastatic
spread and prognosis in patients with breast cancer (Fisher et
al., 1975, 1983; Valagussa et al., 1978) and is the basis for
several prognostic indices (Todd et al., 1987; Galea et al.,
1992). Despite this, the management of the axilla in patients
with screen-detected and early symptomatic breast cancer is
controversial and ranges from no surgical intervention, toAxillary surgery for screen-detected breast cancers
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axillary sampling of ten nodes and to formal level III axillary
clearance. It is not the purpose of this paper to discuss the
relative merits of each of these management options, however
the quality assurance guidelines laid down for surgeons
managing symptomatic breast cancer advise that axillary
surgery of some type must be performed in all cases (British
Association of Surgical Oncologists, 1995).
For screen-detected cancers, our unit policy is to perform
a level III axillary clearance for women considered to be at
significant risk of having nodal metastases (i.e. > 10%). For
patients with cancers at low risk (< 10%) of nodal
involvement, no form of axillary surgery is performed. This
policy is recommended by other authors (Silverstein et al.,
1994; Chada et al., 1994; Cady, 1994) and can be justified if
this important subgroup of women can be accurately
identified preoperatively.
For breast cancers that present symptomatically, axillary
dissection should ideally be performed at the same time as
therapeutic excision of the primary tumour, the diagnosis
having been made preoperatively by fine-needle aspiration
cytology. However, stereotactic cytological assessment of
small impalpable screen-detected cancers can be difficult, and
many of our patients require diagnostic localisation biopsy.
In our previous study, PS-detected cancers < 10 mm
diameter were associated with lymph node metastases in
only 5% of cases. No grade I cancers <30 mm were
associated with nodal involvement. We recommend that this
subgroup of patients can be spared axillary surgery after
localisation biopsy. This reduces morbidity and operating
time, with little loss of prognostic information.
Apart from grade I cancers, this low rate of nodal
metastases was not found in cancers detected at the FIS. For
any given size, cancers detected at our PS have fewer lymph
node metastases than those detected at the FIS (Figure 2).
Their relationship between size and lymph node status seen
for PS- and FIS-detected cancers is similar to that seen
between screen-detected and symptomatic cancers, with the
latter having a higher incidence of nodal involvement (Crisp
et al., 1993). Moreover, the frequency of node metastases in
the FIS-detected cancers is equivalent to that seen in a
symptomatic breast cancer population (Fisher et al., 1983).
The implementation of our previous recommendations led
initially to fewer women with screen-detected cancer under-
going axillary surgery in Manchester, UK. In this study,
patients who did not undergo axillary clearance were
assumed to be lymph node negative, and we calculated
lymph node positivity as a proportion of the total invasive
group, and not just of those undergoing axillary dissection. If
we consider axillary node involvement as a percentage of
those undergoing axillary surgery, the frequency of nodal
metastasis in the FIS cancer is nearly 9% higher at 38.4%.
The incidence of lymph node positivity for non-screened,
symptomatic cancers has been reported to be between 40%
and 50% (Crisp et al., 1993; Fentiman, 1991). Therefore, in
terms of their lymph node status, many of our FIS-detected
cancers behave more like symptomatic than screen-detected
cancers.
The two main prerequisites for a reduction in/breast
cancer mortality from the breast screening programme are (1)
a more favourable stage distribution in screen-detected
cancers, with fewer nodal metastases at presentation, and
(2) a low incidence of cancers presenting with symptoms
between screening rounds (interval cancers). In the North
West Region, the incidence of interval cancers in the third
year after breast screening approaches that which would be
expected in the absence of screening (Woodman et al., 1995).
This suggests that a screening interval of 3 years is too long.
The screening interval may have to be shortened to 2 years to
reduce the incidence of interval cancers. Although no
evidence as yet exists, a shortening of the screening interval
may also be required to reduce the incidence of nodal
metastases in FIS-detected cancers.
In conclusion, knowledge of axillary lymph node status
allows accurate selection of those women requiring systemic
adjuvant chemotherapy. Inadequate staging will result in a
proprotion of these women receiving suboptimum therapy. It
is also imperative to the monitoring of the UK screening
programme, that histological evidence of node status be
available on all patients at high risk of nodal metastases
(Alexander et al., 1994).
We believe that our recommendations for small and well-
differentiated cancers detected at the PS remain valid.
However, in the light of our finding of a higher incidence
of node positivity in FIS-detected cancers (with the possible
exception of grade I cancers), we now consider surgical
staging of the axilla essential for all cancers detected at the
FIS, until more reliable predictors of biological aggressive-
ness and cancer prognosis are identified.
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